(Q36439731)

14 August 2017

1 reference

title

Amifostine in the management of radiation-induced and chemo-induced mucositis (English)

1 reference

14 August 2017

Rene-Jean Bensadoun

1

1 reference

14 August 2017

Mark M Schubert

series ordinal

2

1 reference

14 August 2017

Rajesh V Lalla

series ordinal

3

1 reference

14 August 2017

Dorothy Keefe

series ordinal

4

1 reference

14 August 2017

publication date

4 April 2006

1 reference

Supportive Care in Cancer

14 August 2017

published in

1 reference

14 August 2017

volume

14

1 reference

14 August 2017

issue

6

1 reference

14 August 2017

page(s)

566-572

1 reference

Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection?

14 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00520-006-0047-4

Cytoprotective effect of amifostine in radiation-induced acute mucositis - a retrospective analysis

21 January 2018

1 reference

12 December 2020

Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer

1 reference

12 December 2020

Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis

1 reference

12 December 2020

Rating the quality of evidence for clinical practice guidelines

1 reference

12 December 2020

A pilot study on feasibility and efficacy of amifostine preceding high-dose melphalan with autologous stem cell support in myeloma patients

1 reference

12 December 2020

Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.

1 reference

12 December 2020

Influence of amifostine on toxicity of CHOP in elderly patients with aggressive non-Hodgkin's lymphoma--a phase II study

1 reference

12 December 2020

Intrarectal application of amifostine for the prevention of radiation-induced rectal injury

1 reference

12 December 2020

Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review

1 reference

12 December 2020

Early results from a phase I/II radiation dose-escalation study with concurrent amifostine and infusional 5-fluorouracil chemotherapy for preoperative treatment of unresectable or locally recurrent rectal carcinoma

1 reference

12 December 2020

Rationale for a phase I/II radiation dose-escalation study with concurrent amifostine (Ethyol) and infusional 5-FU chemotherapy for preoperative treatment of unresectable or locally recurrent rectal carcinoma

1 reference

12 December 2020

Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas: results of a randomized trial

1 reference

12 December 2020

Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer

1 reference

12 December 2020

Amifostine, in a reduced dose, protects against severe diarrhea associated with weekly fluorouracil and folinic acid chemotherapy in advanced colorectal cancer: a pilot study

1 reference

12 December 2020

Randomized trials of amifostine and radiotherapy: effect on survival?

1 reference

12 December 2020

Outcome of local application of amifostine (WR-1065) on epirubicin-induced oral mucositis. A phase II study

1 reference

12 December 2020

Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results

1 reference

12 December 2020

Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer

1 reference

12 December 2020

The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).

1 reference

12 December 2020

A randomized trial of amifostine as a cytoprotectant for patients receiving myeloablative therapy for allogeneic hematopoietic stem cell transplantation.

1 reference

12 December 2020

Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy

1 reference

12 December 2020

Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer

1 reference

12 December 2020

Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation

1 reference

12 December 2020

Lack of cytoprotective effect of amifostine following HLA-identical sibling transplantation for advanced myelodysplastic syndrome (MDS): a pilot study

1 reference

12 December 2020

Amifostine as radioprotective agent for the rectal mucosa during irradiation of pelvic tumors. A phase II randomized study using various toxicity scales and rectosigmoidoscopy

1 reference

12 December 2020

Phase II evaluation of amifostine as an esophageal mucosal protectant in the treatment of limited-stage small cell lung cancer with chemotherapy and twice-daily radiation

1 reference

12 December 2020

Impact on cytoprotective efficacy of intermediate interval between amifostine administration and radiotherapy: a retrospective analysis

1 reference

12 December 2020

2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology

1 reference

12 December 2020

Amifostine before chemotherapy: improved tolerance profile of the subcutaneous over the intravenous route

1 reference

12 December 2020

Radiotherapy or chemotherapy followed by radiotherapy with or without amifostine in locally advanced lung cancer

1 reference

12 December 2020

Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma.

1 reference

12 December 2020

Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients.

1 reference

12 December 2020

New dosing regimens for amifostine: a pilot study to compare the relative bioavailability of oral and subcutaneous administration with intravenous infusion

1 reference

12 December 2020

Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients

1 reference

12 December 2020

A pilot study of topical intrarectal application of amifostine for prevention of late radiation rectal injury

1 reference

12 December 2020

A phase III randomized evaluation of amifostine in stage IIIA/IIIB non-small cell lung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification: preliminary findings

1 reference

12 December 2020

Oral candidiasis in head and neck cancer patients receiving radiotherapy with amifostine cytoprotection.

1 reference

12 December 2020

Phase II: trial of twice weekly amifostine in patients with non-small cell lung cancer treated with chemoradiotherapy

1 reference

12 December 2020

Does amifostine have a role in chemoradiation treatment?

1 reference

12 December 2020

10.1007/S00520-006-0047-4

Identifiers

DOI

1 reference

14 August 2017

1 reference